Granules India inaugurated two advanced Centres of Excellence (CoE) at the Technology Research Park of IIT Hyderabad, strengthening its research and development capabilities in peptides and advanced material sciences.
Ascelis CoE for Peptide Development and Characterisation
The Ascelis Center of Excellence, established under Ascelis Peptides, the CDMO arm of Granules India, will focus on cosmetic, therapeutic, and pharmaceutical peptide development. This marks Ascelis’ first development and characterisation facility in India, equipped to perform primary, secondary, and tertiary structure characterisation.
By bringing advanced analytical and process development capabilities in-house, the facility will collaborate with Granules’ Swiss-based R&D partner, Senn Chemicals. This integration strengthens the group’s global peptide offering and reduces dependence on external partners.
Granules CoE for Particle Engineering
As reported by thehindubusinessline.com, the Granules Centre of Excellence for Particle Engineering will advance polymorph research and material science. It will also focus on novel drug delivery systems, including amorphous solid dispersions.
Replacing earlier external and ad-hoc development efforts, this dedicated research platform will:
*Enable first-to-file opportunities
*Enhance formulation performance
*Support the creation of proprietary technologies for regulated markets
The CoE will accelerate innovation in advanced material sciences and reinforce Granules’ position as a technology-driven CDMO.
Leadership Highlights Strategic Impact
“The launch of these Centres of Excellence significantly strengthens our capabilities in peptides and advanced material sciences, areas that will define the next wave of pharmaceutical innovation,” said Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India. “With specialised infrastructure and deep scientific expertise, we are enhancing our CDMO ambitions, accelerating breakthrough development, and building differentiated technologies that elevate our global competitiveness and deliver meaningful value to our partners and patients worldwide,” he added.
